A predictive tool for selecting HBeAg-positive chronic hepatitis B patients who have a high probability of HBV DNA suppression and HBeAg seroconversion with peginterferon alfa-2a

被引：0

作者：

Chan, Henry Lik-Yuen ^{[1
,2
]}

Papatheodoridis, George V. ^{[3
]}

Messinger, Diethelm ^{[4
]}

Bakalos, George ^{[5
]}

Lampertico, Pietro ^{[6
]}

机构：

[1] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China

[3] Univ Athens, Sch Med, Dept Gastroenterol, Laiko Gen Hosp, GR-11527 Athens, Greece

[4] IST GmbH, Mannheim, Germany

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Gastroenterol Unit 1, AM&A Migliavacca Ctr Liver Dis, Milan, Italy

来源：

HEPATOLOGY | 2014年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1886

引用

页码：1108A / 1108A

页数：1

共 50 条

[1] A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B
Chan, H. L. Y.
Messinger, D.
Papatheodoridis, G. V.
Cornberg, M.
Xie, Q.
Piratvisuth, T.
Ren, H.
Kennedy, P. T.
Thompson, A.
Caputo, A.
Bakalos, G.
Pavlovic, V.
Lampertico, P.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (05) : 547 - 555
[2] Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
Lau, GKK
Piratvisuth, T
Luo, KX
Marcellin, P
Thongsawat, S
Cooksley, G
Gane, E
Fried, MW
Chow, WC
Paik, SW
Chang, WY
Berg, T
Flisiak, R
McCloud, P
Pluck, N
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26): : 2682 - 2695
[3] Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B
van Boemmel, Florian
van Boemmel, Alena
Krauel, Alexander
Wat, Cynthia
Pavlovic, Vedran
Yang, Lei
Deichsel, Danilo
Berg, Thomas
Boehm, Stephan
JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (07): : 1066 - 1074
[4] HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Fried, Michael W.
Piratvisuth, Teerha
Lau, George K. K.
Marcellin, Patrick
Chow, Wan-Cheng
Cooksley, Graham
Luo, Kang-Xian
Paik, Seung Woon
Liaw, Yun-Fan
Button, Peter
Popescu, Matei
HEPATOLOGY, 2008, 47 (02) : 428 - 434
[5] A baseline predictive tool for selecting HBeAg-negative chronic hepatitis B patients who have a high probability of achieving sustained immune control with peginterferon alfa-2a
Lampertico, Pietro
Rothe, Vivien
Caputo, Antonietta
Papatheodoridis, George V.
HEPATOLOGY, 2014, 60 : 1107A - 1108A
[6] A practical tool to predict response to peginterferon alfa-2a in Asian patients with HBeAg-positive chronic hepatitis B
Chow, Wan Cheng
Cooksley, Graham
Piratvisuth, Teerha
Lau, George Kk
Mccloud, Philip
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
[7] HBV DNA Suppression in HBeAg-Positive Chronic Hepatitis B Patients Treated With Peginterferon or Placebo
Hansen, Bettina E.
Rijckborst, Vincent
ter Borg, Martijn J.
Janssen, Harry L. A.
JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (11) : 1917 - 1923
[8] Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-positive chronic hepatitis B
Xu, D. -Z.
Xie, Y.
Wei, L.
Chen, X. Y.
Wan, M. -B.
Wang, Y. -M.
Wang, L.
Wei, J.
Gan, J. -H.
Tian, D. -Y.
Zhang, S. -L.
JOURNAL OF HEPATOLOGY, 2008, 48 : S266 - S266
[9] EXTENDING THE TREATMENT DURATION OF PEGINTERFERON ALFA-2A THERAPY TO 72 WEEKS INCREASES THE RATE OF HBeAg SEROCONVERSION IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
Zhu, Y. -Y.
Dong, J.
Chen, Y. -T.
Chen, J.
Jiang, J. -J.
JOURNAL OF HEPATOLOGY, 2009, 50 : S331 - S332
[10] PREDICTORS OF DEVELOPMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B FOLLOWING PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE CHRONIC HEPATITIS B
Peng, Cheng-Yuan
Shih, Chao-Jen
Lo, Pei-Shuan
Huang, Chia-Lin
Lai, Hsueh-Chou
Su, Wen-Pang
Chuang, Po-Heng
Kao, Jung-Ta
HEPATOLOGY, 2011, 54 : 1027A - 1028A

← 1 2 3 4 5 →